Pathogenic bacteria and drug resistance of nosocomial infection in patients with spinal cord injury in rehabilitation stage

doi:10.3877/cma.j.issn.1674-1358.2016.06.016

Abstract

Abstract:

Objective

To investigate the pathogenic bacteria and drug resistance of nosocomial infection in patients with spinal cord injury.

Methods

Total of 400 hospitalized cases with spinal cord injury were selected in our hospital from June 2013 to June 2015, including 136 cases with hospital infection. MicroScan WalkAway microbe drug susceptibility test system was applied to isolate infected bacteria identification and drug sensitive test samples, and the pathogenic bacteria and drug resistance of spinal cord injury patients with hospital infection during rehabilitation phase were analyzed.

Results

There were 136 cases with hospital infection among 400 cases with spinal cord injury, the infection rate was 34%. The distribution of nosocomial infection in patients with spinal cord injury was relatively wide, mainly distributed in the urinary tract (68.42%) and lower respiratory tract (23.03%). The main pathogenic bacteria of nosocomial infection in patients with spinal cord injury were Escherichia coli (44.74%) and Pseudomonas aeruginosa (18.42%). Drug resistance of patients with spinal cord injury and nosocomial infection were high, which were 4.41% and 8.82% of Escherichia coli to piperacillin tazobactam and cefoperazone sulbactam. While the resistance rates of Pseudomonas aeruginosa to piperacillin tazobactam, cefoperazone sulbactam, ISO pamidronate star and amikacin were all 0.00%, and Klebsiella pneumoniae to piperacillin sodium and cefoperazone sulbactam were 17.65% and 0.00%.

Conclusions

The sites of nosocomial infection for patients with spinal cord injury were mainly urinary tract and respiratory tract, mainly Escherichia coli and Pseudomonas aeruginosa, with high drug resistance.

Key words: Convalescence, Spinal cord injury, Hospital infection, Pathogenic bacteria, Drug resistance

Yuhong Tian, Lixia Zhang, Li Cheng, Gaoliang Cui. Pathogenic bacteria and drug resistance of nosocomial infection in patients with spinal cord injury in rehabilitation stage[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(06): 725-728.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2016.06.016

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2016/V10/I06/725

Figures/Tables 3

References 25

1	吕卫华，卫金歧，赵君. 脊髓损伤患者医院感染常见部位分析及护理干预[J]. 中华医院感染学杂志,2011,21(14):2909-2010.
2	Chou YC. Medial gastrocnemius muscle flap for treating wound complications after double-plate fixation via two-incision approach for complex tibial plateau fractures[J]. J Trauma,2010,68(1):138-145.
3	Thomas V, Matthew FB, Jeremy TS, et al. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections[J]. J Med Chem,2013,56(12):5079-5093.
4	杨慧宁，王鲜平，张娜, 等. 呼吸机相关性肺炎的病原菌分布及耐药性研究[J]. 中华医院感染学杂志,2012,22(3):632-634.
5	Ghoi HJ, Paeng SH, Kim ST, et al. The effectiveness of early tracheostomy (within at least 10 days) in cervical spinal cord injury patients[J]. Korean Neurosurg Soc,2013,54(3):220-224.
6	Garnacho-Montero J, Corcia-Palomo Y, Amaya-VillarR, et al. How to treat VAP due to MDR pathogens in ICU patients[J]. BMC Infect Dis,2014,135(14):1-7.
7	Pittavat L, Jennifer CF, Kevin RG, et al. Predicting the need for traeheostomy in patients with cervical spinal cord injury[J]. J Trauma Acute Care Surg,2012,73(4):880-884.
8	Pannek J. Treatment of urinary tract infection in persons with spinal cord injury: guidelines, evidence and clinical practice. A questionnaire-based survey and review of the literature[J]. Spinal Cord Med,2011,34(1):11-15.
9	王元姣. 高位脊髓损伤患者医院感染危险因素分析及对策[J]. 浙江医学,2012,34(7):519-521.
10	徐广辉，张咏，满毅, 等. 急性颈椎脊髓损伤肺部感染特点及早期救治[J]. 中华医学杂志,2013,93(5):352-356.
11	古正涛，邓小玲，郑国栋, 等. 颈脊髓损伤患者医院获得性肺炎及其病原菌分析[J]. 中国脊柱脊髓杂志,2011,21(1):33-37.
12	刘申. 腰椎脊髓损伤患者并发尿路感染的相关危险因素研究[J]. 河北医学,2012,18(5):647-649.
13	吴安华，文细毛，李春辉, 等. 2012年全国医院感染现患率与横断面抗菌药物使用率调查报告[J]. 中国感染控制杂志,2014,13(1):8-15.
14	Adan R, Tarallo L, Amorico MG, et al. The treatment of distal radius articular fractures through LCP system[J]. Hand Surg,2012,13(2):61-64.
15	刘西花，高杰，岳寿伟. 脊髓损伤患者尿路感染的影响因素研究[J]. 中华康复医学杂志,2011,26(3):261-262.
16	胡忠春，赵明，张文. 泌尿外科患者医院感染病原菌分布与感染危险因素分析[J]. 中华医院感染学杂志,2015,25(1):199-201.
17	毛容秋，蒋竞杭，彭慧. 脊髓损伤患者康复期尿路感染的危险因素[J]. 中华康复医学杂志,2010,25(10):958-962.
18	Laible C, Earl-Royal E, Davidovitch R, et al. Infection after spanning external fixation for high-energy tibial plateau fractures: is pin site-plate overlap a problem[J]. J Orthopaedic Trauma,2012,26(2):92-97.
19	Berney S, Bragge P, Granger C, et al. The acute respiratory management of cervical spinal cord injury in the first 6 weeks after injury:a systematic review[J]. Spinal Cord,2011,49(1):17-29.
20	伍娟英，张斌，姜熙, 等. 329例尿路感染常见细菌分布及耐药性分析[J]. 检验医学与临床,2014,11(9):1244-1245.
21	Gatherine GJ, Leilani Jean BH. Pulmonary management of the acute cervical spinal cord injured patients Pulmonary management[J]. Nuts Clin North Am,2014,49(3):357-369.
22	阳志勇，匡艳华，刘双全, 等. 耐碳青霉烯类铜绿假单胞菌的药物敏感性与耐药机制研究[J]. 中华医院感染学杂志,2012,22(23):5181-5183.
23	卢守四，高钧. 脊髓损伤并发尿路感染的菌群分布及药物治疗[J]. 中国康复理论与实践,2011,17(8):758-760.
24	赵国伟，高钧. 395例脊髓损伤患者医院感染的病原菌分布和耐药情况分析[J]. 中国康复理论与实践,2015,21(4):460-463.
25	宛传丹，周金保，马月琴, 等. 神经外科住院患者医院感染病原菌特征与危险因素分析[J]. 山东医药,2015,55(8):89-91.

感染部位	株数	构成比（%）
泌尿道	104	68.42
下呼吸道	35	23.03
上呼吸道	4	2.63
血液	3	1.97
胃肠道	2	1.32
皮肤软组织	2	1.32
其他	2	1.32
合计	152	100.00

感染部位	株数	构成比（%）
泌尿道	104	68.42
下呼吸道	35	23.03
上呼吸道	4	2.63
血液	3	1.97
胃肠道	2	1.32
皮肤软组织	2	1.32
其他	2	1.32
合计	152	100.00

病原菌	株数	构成比（%）
大肠埃希菌	68	44.74
铜绿假单胞菌	28	18.42
肺炎克雷伯菌	17	11.18
奇异变形杆菌	13	8.55
金黄色葡萄球菌	12	7.89
阴沟肠杆菌	4	2.63
其他	10	6.58
合计	152	100.00

病原菌	株数	构成比（%）
大肠埃希菌	68	44.74
铜绿假单胞菌	28	18.42
肺炎克雷伯菌	17	11.18
奇异变形杆菌	13	8.55
金黄色葡萄球菌	12	7.89
阴沟肠杆菌	4	2.63
其他	10	6.58
合计	152	100.00

抗菌药物	大肠埃希菌（n = 68）		铜绿假单胞菌（n = 28）		肺炎克雷伯菌（n = 17）
抗菌药物	耐药株数	耐药率（%）	耐药株数	耐药率（%）	耐药株数	耐药率（%）
头孢呋辛	32	47.06	28	100.00	13	76.47
环丙沙星	55	80.88	22	78.57	13	76.47
左氧氟沙星	46	67.65	23	82.14	11	64.71
氨曲南	29	42.65	18	64.29	12	70.59
头孢曲松	33	48.53	14	50.00	6	35.29
依替米星	22	32.35	13	46.43	8	47.06
头孢西丁	7	10.29	26	92.86	6	35.29
头孢他啶	22	32.35	6	21.43	10	58.82
哌拉西林/他唑巴坦	3	4.41	0	0.00	3	17.65
头孢哌酮/舒巴坦	6	8.82	0	0.00	0	0.00
异帕米星	13	19.12	0	0.00	6	35.29
阿米卡星	9	13.24	0	0.00	5	29.41

Please choose a citation manager

Content to export